StockComparison Logo
vs

SGTX vs PMVP

Comparison between Sigilon Therapeutics Inc (SGTX, Company) and PMV Pharmaceuticals Inc (PMVP, Company).

SGTX vs PMVP - Performance Comparison

Key Characteristics

Financial metrics and valuation ratios

Market Cap
SGTX
$56M
Winner
PMVP
$57M
Max Drawdown
SGTX
99.39%
Winner
PMVP
98.64%
Sharpe Ratio
Winner
SGTX
0.95
PMVP
0.17
5Y Beta
SGTX
N/A
PMVP
0.64
Industry
SGTX
N/A
PMVP
Biotechnology
P/E Ratio
Winner
SGTX
-1.85
PMVP
-0.72
PEG Ratio
SGTX
N/A
PMVP
-0.03
5Y EPS CAGR
SGTX
N/A
PMVP
5.51%
Debt to Equity
SGTX
0.00%
PMVP
0.00%
Free Cash Flow Yield
SGTX
-59.21%
PMVP
N/A
P/S Ratio
SGTX
3.18
PMVP
N/A
P/B Ratio
SGTX
2.05
Winner
PMVP
0.65

SGTX vs PMVP - Historical Returns

Returns include dividend reinvestment.

1M
Winner
SGTX
+3.84%
PMVP
-21.83%
3M
Winner
SGTX
+245.69%
PMVP
-29.75%
6M
Winner
SGTX
+161.89%
PMVP
-9.76%
1Y
Winner
SGTX
+130.62%
PMVP
+1.83%
5Y(CAGR)
SGTX
N/A
PMVP
-49.66%
Max(CAGR)
SGTX
-67.33%
Winner
PMVP
-46.01%

SGTX vs PMVP - Annual Returns (2020 - 2026)

Returns include dividend reinvestment.

YearSGTXPMVP
2026N/A-9.76%
2025N/A-18.30%
2024N/A-51.60%
2023+401.00%-63.44%
2022-88.45%-63.06%
2021-92.97%-53.10%
2020+38.10%+63.98%

SGTX vs PMVP Drawdown Comparison

The maximum drawdown for SGTX was -99.39%, occurring on Dec 27, 2022. This drawdown has not yet recovered.

The maximum drawdown for PMVP was -98.64%, occurring on May 15, 2025. This drawdown has not yet recovered.

The current SGTX drawdown is -96.40%. The current PMVP drawdown is -98.20%.

RankSGTXPMVP
#1-99.39%
Dec 31, 2020 - Dec 27, 2022
-98.64%
Dec 31, 2020 - May 15, 2025
#2-20.64%
Dec 4, 2020 - Dec 21, 2020
-16.16%
Sep 29, 2020 - Dec 3, 2020
#3-17.66%
Dec 22, 2020 - Dec 31, 2020
-12.65%
Dec 23, 2020 - Dec 31, 2020
#4N/A-6.51%
Dec 4, 2020 - Dec 11, 2020
#5N/A-6.44%
Dec 11, 2020 - Dec 22, 2020
#6N/A-3.52%
Sep 25, 2020 - Sep 29, 2020

Correlation

Correlation between SGTX and PMVP is 0.85 which considered as a strong positive correlation - the stocks tend to move together.

0.85
-101

Select Stocks to Compare